EDG 007

Drug Profile

EDG 007

Alternative Names: EDG-007

Latest Information Update: 08 Dec 2014

Price : $50

At a glance

  • Originator Edgemont Pharmaceuticals
  • Class
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Vasomotor symptoms

Highest Development Phases

  • Phase Unknown Vasomotor symptoms

Most Recent Events

  • 08 Dec 2014 Investigation in Vasomotor symptoms in USA (unspecified route)
  • 08 Dec 2014 EDG 007 is available for licensing in World as of 08 Dec 2014. http://edgemontpharma.com/
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top